, an analyst from TD Cowen, reiterated the Buy rating on Aurora Cannabis. The associated price target is C$10.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TD Cowen has given his Buy rating due to a combination of factors related to Aurora Cannabis’s strategic moves and earnings outlook. The firm views the divestiture of Aurora’s plant propagation business as a sensible step that should enhance profitability, reduce operational complexity, and help stabilize margins. They also believe that this transaction helps clear up some overhang and business-model uncertainty without requiring a change to their broader investment thesis or long-term projections.
TD Cowen’s outlook further reflects confidence that Aurora’s growth profile is set to improve, with expectations for a return to positive revenue expansion by Q2/F26. In their view, this turning point, alongside a cleaner corporate structure and improved earnings quality, supports the notion that the company is heading into a more constructive phase. Taken together, the margin uplift from divestiture, reduced risk profile, and anticipated resumption of growth underpin their decision to maintain a C$10.00 price target and a Buy recommendation on ACB.
In another report released today, ATB Capital Markets also maintained a Buy rating on the stock with a C$8.50 price target.